COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability (NCT05584189), a non-randomized na study. The primary outcome is 30 Candidate Ag Test Self-collections.

2. Clinical Question

The practical question is whether lay users could carry out the candidate kit’s anterior nasal specimen collection and testing in a supervised, in-person usability setting. One participant role involved self-collection and self-testing; the other involved collecting a specimen from another participant and testing the kit. The registry record identifies at least 30 participants for each role in the arm descriptions, and reports 53 participants at risk in the self-testing group and 46 in the group testing another participant in its adverse-event data.

This is a usability question rather than a randomized comparison of clinical outcomes. The record does not describe a control test or a comparison intended to estimate a treatment effect. It also does not report diagnostic accuracy results, such as agreement with another test, so the usability objective should not be read as an assessment of test performance.

3. Trial Design

The registry record describes a completed study of the Rapid SARS-CoV-2 Antigen Test, a device intervention. Its model is listed as single group, with non-randomized allocation and no masking. The study is titled “COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability”; its official title is “Over the Counter Rapid Antigen Test for Detection of SARS-CoV-2 Virus: Human Usability Study.” The sponsor is MP Biomedicals, LLC, and the phase is listed as NA.

The record gives enrollment as 99. It describes two participant roles. In one, people aged 14-65+ years performed anterior nasal specimen collection and testing on themselves. In the other, participants aged 18-65+ years collected an anterior nasal specimen from another participant aged 2-65+ years and tested the kit. Qualified site personnel supervised both activities in person. The group-specific adverse-event records list 53 participants at risk in the self-testing group and 46 in the group testing another participant.

Although the record lists two groups, it explicitly cautions that the allocation was non-randomized and that the arms are not a like-for-like control comparison. The groups reflect different user tasks, not randomized assignments to competing interventions. Differences between their counts or experiences therefore cannot be interpreted as causal effects of one task or intervention relative to another.

The study start date is 2021-10-07, the primary completion date is 2021-10-27, and status is completed. The registry record does not report a detailed protocol, a sample-size justification, or the procedures used to recruit participants. It also does not report how usability was scored, what constituted successful completion, or how deviations from the test instructions were handled.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: The second arm of the trial was analyzed under the second primary outcome measure. This is why the number is 0 for this outcome measure.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as 30 Candidate Ag Test Self-collections, measured over One Hour.

The listed primary outcome is titled “30 Candidate Ag Test Self-collections.” Its unit is participants, its measure is a count of participants, and its timeframe is one hour. The description identifies lay subjects aged 14-65+ years who perform collection with the candidate antigen self-test kit on themselves under the in-person supervision of qualified site personnel.

A participant count can describe how many people completed or were associated with a specified usability task, depending on the outcome’s operational definition. In general, a count is a descriptive measure; by itself, it does not establish whether users collected specimens correctly, followed instructions, obtained valid results, or achieved a particular level of usability. The registry record does not report those definitions or results for this measure.

The record explains that the second arm was analyzed under a second primary outcome measure and that the number for this outcome measure is 0. That registry entry should not be interpreted as evidence that zero participants performed self-collection. It describes how the primary outcome measure is recorded, while the adverse-event data separately list 53 participants at risk in the self-testing group. No primary outcome result is reported in the registry record, so the count and its meaning cannot be assessed as an observed usability result.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record characterizes the primary outcome as a count of participants and gives a one-hour timeframe. Counts are descriptive: they record how many participants meet a specified definition. To interpret a usability count, readers need to know the operational definition, such as whether the count represents starting a task, completing a task, or completing it according to instructions. That definition and an observed result for this primary outcome are not reported in the registry record.

What does the recorded zero mean?

The primary outcome information says that the second arm was analyzed under a second primary outcome measure, which is why the number for this outcome measure is 0. This is a statement about the registry’s outcome entry. It should not be treated as an observed count of people who did not self-collect. The adverse-event record separately lists 53 participants at risk in the self-testing group, but that safety count is not a usability endpoint result. The registry record does not report the result for the primary outcome measure or define a second primary outcome’s result.

How should uncertainty be understood?

In general, a confidence interval describes a range of values compatible with data under a specified statistical method and assumptions. Its width conveys precision: a wider interval indicates greater uncertainty about the estimate. A p value, in general, measures how surprising data at least as incompatible with a specified null model would be if that model and its assumptions held. Neither measure is reported for the primary outcome in the registry record. Without an observed endpoint value and its analysis, the size and precision of a usability result cannot be evaluated.

In general, counts may be analyzed using methods for count outcomes, while proportions may be analyzed using methods for binary outcomes. The appropriate approach depends on the endpoint definition, the data structure, and the analysis plan. The record gives the primary unit as participants and the measure as a count, but it does not report a statistical analysis plan or any analyses. The registry record therefore does not establish which inferential method, if any, was used for the primary outcome.

Why does the study design matter?

Random allocation can help balance measured and unmeasured participant characteristics across comparison groups. This study is listed as non-randomized, and the record warns that its arms are not a like-for-like control comparison. The groups also perform different tasks: one involves self-testing, while the other involves testing another participant. Any observed difference between their counts would not, by itself, isolate a causal effect of the test or task. No randomized comparator is reported.

The model is listed as single group, despite the description of two participant roles. The roles should be understood from their task descriptions, rather than treated as randomized treatment arms. No masking is listed. The record does not report whether outcome assessors were blinded, how supervision may have influenced performance, or whether tasks were scored by a prespecified rubric.

What can planning illustrations tell readers?

In general, a sample-size calculation describes the amount of information a planned study might need to detect a specified effect under stated assumptions. Such a calculation is not a study result and is not “observed power.” The registry record describes planning illustrations based on the observed effect, with a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation; the effect to detect is a stated fraction of the observed effect. These are planning assumptions, not evidence that the trial was designed using those assumptions. The registry record does not report its own sample-size justification. The planning illustration is not a substitute for an observed endpoint estimate and its uncertainty.

In general, over-dispersion occurs when count data vary more than a particular model expects. If present, it can make model-based standard errors too small unless the analysis accounts for that extra variability. No count-model results, dispersion estimate, or approach to over-dispersion is reported in the registry record. This concept therefore explains a general consideration for count analysis, not a feature established for these study data.

What information is needed to reproduce an analysis?

Reproducible interpretation requires a defined analysis population, endpoint rules, handling of missing observations, and a description of the statistical method. It also requires enough outcome data to reproduce estimates and assess uncertainty. The registry record lists zero analyses and does not report these details for the primary outcome. The reported enrollment and adverse-event counts alone cannot reproduce a usability analysis or determine whether the test tasks were performed successfully.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("At Least 30 Persons 14-65+ Years of Age Who Test T")
n      <- c(53)
events <- c(53)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  At Least 30 Persons 14-65+ Years of Age Who Test T  53  53  100.0  93.3  100.0  93.2  100.0  93.4  100.0

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists three outcome measures and zero analyses. It names one secondary outcome: “At Least One Enrollment of a Spanish Speaking Lay User.” No result for that secondary outcome is reported in the registry record. The primary outcome information also says that the second arm was analyzed under a second primary outcome measure, but the other primary outcome’s definition and result are not reported in the registry record.

When a study assesses multiple outcomes, multiplicity can arise because repeated statistical tests increase the chance of at least one false-positive finding if each test is interpreted separately. In general, a prespecified analysis plan can explain which outcomes are primary, how multiple tests will be handled, and which comparisons are confirmatory. The registry record does not report a multiplicity adjustment, an analysis hierarchy, or the statistical plan. Since no analysis results are listed, there are no posted p values or confidence intervals whose multiplicity handling can be evaluated.

Missing-data handling is also not reported in the registry record. The record does not say whether all enrolled participants completed their assigned tasks, whether any observations were unavailable, or how missing usability or safety information was treated. It does not define the analysis population for the primary outcome. Enrollment of 99 and the group-specific adverse-event counts do not establish completeness for the usability endpoint.

These omissions limit interpretation rather than establishing that data were missing or that a particular analysis choice was made. Without endpoint definitions, analysis populations, missing-data rules, and analysis methods, readers cannot assess whether results were calculated on all enrolled participants or a subset, or whether outcome reporting followed a prespecified plan.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The adverse-event record lists 53 participants at risk in the group of persons aged 14-65+ years who tested themselves, and 46 at risk in the group of persons aged 18-65+ years who tested another participant. In both groups, the posted serious adverse-event count is 0, the other adverse-event count is 0, and deaths are recorded as 0. These are the reported counts for the groups, not estimates of risk in all users of the test.

A zero count means that no event of that category is recorded in the registry’s group data. It does not establish that no event occurred outside the recorded collection or follow-up, nor does it prove that the risk is absent. General interpretation of safety counts depends on how events were defined, collected, attributed, and followed. Those details are not reported in the registry record. The record also does not report a safety analysis or a comparison designed to estimate differences between user roles.

The groups perform different tasks and were not randomized as a like-for-like comparison. Their event counts should therefore be read as separate descriptive records, not as evidence that one task is safer than another. The record lists no serious adverse-event terms among the top serious terms. That is consistent with the reported zero serious adverse-event counts, but does not add information about how safety was monitored.

13. What the Result Does, and Does Not, Mean

The posted information identifies a completed, supervised usability study of the Rapid SARS-CoV-2 Antigen Test and describes two kinds of lay-user task: self-collection and testing, and collection from another participant followed by testing. It reports enrollment of 99 and provides group-specific counts for adverse events and deaths. Those details help characterize the study setting and the recorded safety information.

The record does not report a result for the primary usability outcome. Its primary outcome entry says the second arm was analyzed under a second primary outcome measure and records the number for this measure as 0; the record explains this is why the value is 0 for the measure. That entry should not be interpreted as evidence that no participant performed self-collection. The record also does not report task success, collection quality, user errors, test-result validity, or results for the listed secondary outcome.

Without an observed usability estimate, readers cannot assess the magnitude or precision of task performance. No confidence interval, p value, or analysis result is reported. The registry record therefore does not establish whether users could complete tasks successfully at a particular rate, how usability differed between tasks, or whether the device performed accurately.

The zero adverse-event and death counts describe the entries in the registry record, but do not prove that risk is absent. The record does not describe safety follow-up or event ascertainment in enough detail to assess the completeness of those counts. Similarly, the study’s non-randomized design and distinct participant roles do not support causal comparisons between groups.

In general, usability findings from a supervised setting may not describe performance in every context. The registry record specifically describes in-person supervision by qualified site personnel; it does not report whether results generalize to unsupervised use. The study should therefore be understood through the limited details it records, without treating its design description or safety counts as evidence of unreported outcomes.

14. Why This Trial Matters Statistically

Usability studies address a different question from trials that compare clinical outcomes. For a self-test, the ability of intended users to carry out specimen collection and testing is a relevant part of understanding how the device is used. This registry record makes that purpose clear by describing lay users performing anterior nasal specimen collection and testing under in-person supervision.

Statistically, the record also illustrates why endpoint definition and reporting matter. A count of participants is interpretable only when readers know what qualifies a participant for inclusion in that count and can see the observed result. Here, the primary outcome is titled as a count of candidate antigen test self-collections over one hour, yet the record explains that the second arm was analyzed under a second primary measure and records 0 for this measure. That is not a result showing zero self-collections. The outcome result itself is not reported in the registry record.

The distinction between task groups matters as well. Participants testing themselves and participants testing another person undertake different activities. Since allocation is non-randomized and the record says the arms are not a like-for-like control comparison, their counts cannot be treated as causal evidence about relative performance. A design description must be matched to the question an analysis can answer.

Finally, recording zero adverse events and deaths is not equivalent to demonstrating no risk. Counts need context about ascertainment, follow-up, and event definitions. The registry record supplies group counts but does not report those details, the primary usability result, or analyses. The statistical importance of this study is therefore as much about identifying what the registry does not establish as about reading the counts it does report.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The central limitation for interpretation is that the registry record does not report the primary usability outcome result. The outcome entry records 0 because the second arm was analyzed under a second primary outcome measure; it should not be read as an observed zero for self-collection. The other primary outcome’s definition and result are not reported in the registry record, so the listed primary measure cannot be evaluated against a second outcome.

The record does not define successful task completion, explain how usability was scored, or report counts of completed tasks, errors, invalid tests, or deviations from instructions. It does not report diagnostic accuracy or comparison with a reference method. Consequently, the study description alone cannot support conclusions about test performance or the frequency of successful use.

The study is non-randomized and the user roles involve different tasks. The record explicitly cautions that the arms are not a like-for-like control comparison. No causal comparison between the groups is justified by their separate records. The study was conducted with in-person supervision by qualified site personnel; whether the results apply to unsupervised use is not reported in the registry record.

For safety, the registry lists zero serious adverse events, other adverse events, and deaths in both groups, but does not report event definitions, collection methods, follow-up duration, or attribution. It is therefore not possible to judge the completeness of safety ascertainment from the counts alone.

Other details relevant to appraisal are not reported in the registry record, including recruitment procedures, a sample-size justification, the analysis plan, the analysis population, and missing-data handling. The record lists three outcome measures and zero analyses, limiting assessment of outcome reporting and statistical uncertainty. These gaps do not establish that particular methods were or were not used; they limit what can be concluded from the registry record.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability — NCT05584189.
• Registry record last updated 2023-06-02; status last verified 2022-10.
• Results first posted 2023-06-02.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

This completed, non-randomized usability study evaluated the Rapid SARS-CoV-2 Antigen Test in supervised, in-person tasks. The record describes participants aged 14-65+ years testing themselves and participants aged 18-65+ years testing another participant aged 2-65+ years. Enrollment is 99; the adverse-event records list 53 participants at risk in the self-testing group and 46 in the group testing another participant.

The primary outcome is a participant count titled “30 Candidate Ag Test Self-collections,” with a one-hour timeframe. The registry record explains that the second arm was analyzed under a second primary outcome measure and records 0 for this measure. No primary outcome result or analyses are reported. The listed secondary outcome concerns enrollment of a Spanish speaking lay user, but no result is reported.

Both groups have recorded counts of 0 for serious adverse events, other adverse events, and deaths. Safety-collection details are not reported in the registry record. The non-randomized, distinct-task design does not provide a like-for-like control comparison.